The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) drugs in development market research report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) by 32 companies/universities/institutes. The top development phase for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) is preclinical with 21 drugs in that stage. The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline has 38 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline products market are: Inhibikase Therapeutics, Teva Pharmaceutical Industries and ProMIS Neurosciences.
The key targets in the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline products market include Alpha Synuclein, Tyrosine Protein Kinase ABL1, and Glutamate Ionotropic Receptor NMDA Type Subunit.
The key mechanisms of action in the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline product include Alpha Synuclein Inhibitor with 17 drugs in Phase II. The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline products include nine routes of administration with the top ROA being Oral and eight key molecule types in the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline products market including Small Molecule, and Gene Therapy.
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) overview
Multiple system atrophy (MSA), or Shy-Drager syndrome, is a neurological disorder that impairs the body’s involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson’s medications.
For a complete picture of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
